An open source pharma roadmap by Balasegaram, M et al.
ESSAY
An open source pharma roadmap
Manica Balasegaram1, Peter Kolb2, John McKew3¤a, Jaykumar Menon4, Piero Olliaro5,6,
Tomasz Sablinski7, Zakir Thomas8¤b, Matthew H. Todd9*, Els Torreele10, John Wilbanks11
1 Me´decins Sans Frontières, Geneva, Switzerland, 2 Department of Pharmaceutical Chemistry, Philipps-
University Marburg, Marburg, Germany, 3 National Institutes of Health, National Center for Advancing
Translational Sciences (NCATS), Bethesda, Maryland, United States of America, 4 McGill University Institute
for the Study of International Development, Montreal, Canada, 5 UNICEF/UNDP/World Bank/WHO Special
Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva,
Switzerland, 6 Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine,
University of Oxford, Oxford, United Kingdom, 7 Transparency Life Sciences, New York, New York, United
States of America, 8 Open Source Drug Discovery, Council of Scientific and Industrial Research (CSIR), New
Delhi, India, 9 School of Chemistry, The University of Sydney, Sydney, Australia, 10 Public Health Program,
Open Society Foundations, New York, New York, United States of America, 11 Sage Bionetworks, Seattle,
Washington, United States of America
¤a Current address: Lumo Pharma, Austin, Texas, United States of America
¤b Current address: Directorate of Risk Assessment, Government of India, New Delhi, India
* matthew.todd@sydney.edu.au
Summary points
• This Essay outlines how open source methods of working could be applied to the dis-
covery and development of new medicines.
• There are many potential advantages of an open source approach, such as improved effi-
ciency, the quality and relevance of the research, and wider participation by the scien-
tific and patient communities; a blend of traditional and innovative financing
mechanisms will have to be adopted.
• To evaluate properly the effectiveness of an open source methodology and its potential
as an alternative model of drug discovery and development, we recommend that new
projects be trialed and existing projects scaled up.
Where we stand
The scientific and medical community has discovered and developed many groundbreaking
medicines that have had a major impact on public health. However, drug development is chal-
lenged by a widening gap between health needs and the pharmaceutical industry’s motives and
business model, alongside a decrease in efficiency per research dollar spent in medicinal prod-
uct research and development (R&D), a trend known colloquially as Eroom’s Law [1].
Such fundamental challenges result in frequent high-level calls for new initiatives to develop
therapeutics and bring them to market [2,3]. These include market push and pull mechanisms
such as priority review vouchers, advance market commitments, and public R&D funding [4].
New organizational models have also emerged, including public–private partnerships (PPPs)
[5] and not-for-profit product development partnerships (PDPs) (for example, the Drugs for
Neglected Diseases Initiative [DNDi], the Medicines for Malaria Venture [MMV], and the
Global Alliance for Tuberculosis Drug Development [TB Alliance]) that often apply a full “de-
linkage” model in which the price of medicines and the cost of R&D are uncoupled [6,7].
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Open source pharma
An approach that has been suggested [8] but not yet fully evaluated is open source pharma.
The term “open source” (OS) refers to radically transparent working practices pioneered in
software development, such as the prepublication sharing of data and ideas, the possibility of
participation in a project by anyone in real time, and a form of shared ownership that ensures
that the underlying methods and data are public domain. In OS pharma, such principles
would be applied from the discovery of a potential medicine through to its entry into the mar-
ket; the impact of this, and the ease with which such principles can be applied, will vary at each
stage of the process.
OS must be distinguished from “open innovation” (OI), a term used widely in the pharma-
ceutical industry [9]. Both are characterized by a flow of ideas between problem owners and
solvers, and both therefore harness the potential of unexpected contributions. In a typical OI
initiative, it is the research problem that is public domain, while research solutions are subject
to the usual structures of walled competition. In OS, the problem and all potential solutions
are public domain.
OS brings the greatest possible community involvement, but the transparency brings eco-
nomic uncertainty in how to exploit the solutions. The underlying financial and legal struc-
tures of the pharmaceutical industry are designed for use by profit-making entities in ways
that rely on monopolies, usually through patents. Under the current model, it is assumed that
without exclusive ownership, there can be no guarantee of profit to shareholders—a disincen-
tive for private sector investment in certain areas of health R&D, despite significant public
investments. The requirement for a financial return causes the current system to follow priori-
ties that can be misaligned with the greatest public health needs. The requirement for secrecy
inevitably reduces the efficiency of the scientific research. The transparency at the heart of
OS is thus fundamentally incompatible with traditional approaches to drug discovery and
development. The involvement of the pharma industry in consortia that address neglected or
tropical diseases (e.g., the Tuberculosis Drug Accelerator, which is invitation only and has no
commitment to open data) ensures that a similar walled approach is usually taken even for dis-
eases traditionally considered to yield a low return on investment.
Thus, while OS working practices are well established in some areas of software develop-
ment and have a growing impact in increasing the efficiency of basic science, they have not yet
been broadly applied in medical product R&D, either in academia or industry [10]. It is tempt-
ing to ascribe this to an obvious distinction: software centers on a nonphysical entity (code)
that may be easily copied. Drug R&D involves tangible, lengthy, and often expensive processes.
Yet, this is to obfuscate the more important point: OS is a core set of principles (defining a way
of working) that can be applied quite broadly.
We propose that OS methods are a promising, yet largely untested, way to (1) increase the
efficiency of the research process and (2) realign R&D to address the most pressing public
health problems as opposed to the most promising market opportunities. The main disadvan-
tage of OS is the uncertainty as to how it can be financed, due to the lack of a precedent. We
foresee that approaches can be refined as more projects are developed following these princi-
ples and experience accumulates.
The origin of this Essay lies in several meetings that took place to try to break this deadlock,
beginning with a series of roundtable discussions [11]. There is a great deal yet to consider,
debate, and try; and, as usual, the devil is in the details. This Essay is accompanied by a docu-
ment (S1 Text) that lays out how the traditional structure of drug discovery and development
would be impacted by an OS approach, and readers interested in the detail of the argument are
directed there.
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How OS pharma might be applied
Medical R&D should respond to specific priority health needs. Opening up the R&D process
to a wide range of contributors and stakeholders will allow the design of medicines that are
better adapted to the needs of the end users, and will define the preferred product characteris-
tics (PPCs) and target product profile (TPP) that will guide all the phases of product develop-
ment. In OS, there are no insiders, meaning that strategic decisions may be made through
informed community debate against the agreed-upon TPP. The broader community is thus
involved in designing how a product will be developed, defining the studies that will be done,
and establishing the criteria that will be applied for making stop/go decisions. In order to
achieve this, investments are needed to build online communities and platforms that help
groups collaborate effectively.
In the early stages of drug discovery, involving compound screening and analog synthesis,
there is a clear argument for an open community approach. Indeed, there is early precedent
in this area, such as the crowdsourcing of bioinformatics [12], compound sharing [13,14] or
screening [15–17] services, open-access target validation [18], and OS medicinal chemistry
campaigns [19]. Project objectives can be tackled by any interested researcher or institution,
and certain research problems would be amenable to solution by crowdsourcing from
large student cohorts, for example. Incentives to participate will rely on a mixture of selfless
(improving a public good) and selfish (publication authorship and community acclaim)
motives that are compatible with both academia and industry, where such activities could be
formally sanctioned (e.g., crowdsourced undergraduate lab classes, and strategic or pro bono
industry contributions) or carried out informally (e.g., strategic advice, honest brokership, and
student mentorship). Such motivations have been found to govern participation in OS soft-
ware projects [20]. There is a great and acknowledged potential for greater transparency in
these earlier stages, which, while often termed “pre-competitive,” are nonetheless traditionally
secretive.
As a candidate compound moves through development, the stakes are raised, and data
become more complex and expensive to generate. The OS approach offers a number of advan-
tages: broad stakeholder involvement has the potential to design trials that are better fit for
purpose, as they include the views and requirements of both patients and health providers as
to the key outcome measures, and enjoy contributions to study design and analysis by a range
of experts in the field [21]. Clearly, there is an important responsibility borne by the commu-
nity leaders of any OS endeavor to act as ultimate decision makers (“benign dictators” in soft-
ware parlance) when a broad range of opinions are expressed or inputs received. As data are
generated, there is a public-health imperative to make these data available in a timely fashion
[22,23]. The continual process of transparent, unrestricted peer review of data at the heart of
OS produces outcomes that may ultimately be more robust. Examples of different models
whereby clinical data are being shared have started to accumulate, e.g., in the public and not-
for-profit sector (the TB-Platform for Aggregation of Clinical TB Studies [TB-PACTS] for
tuberculosis [24], the WorldWide Antimalarial Resistance Network [WWARN] for malaria
[25], and the Infectious Diseases Data Observatory [IDDO] for Ebola [26]) as well as in the
pharmaceutical industry (Clinical Study DataRequest [27]); clearly, in any such platform it is
essential that patient confidentiality be protected. Transparency will help to ensure that the
clinical research meets all current ethical criteria and that the appropriate standards are not
compromised by any push to reduce costs.
An area in which OS could be particularly productive is drug repurposing, whereby existing
drugs or candidates are found to have potential for the treatment of another disease and for
which there exists a significant amount of preclinical and possibly clinical data; this is a
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strategy of interest for the recent Zika outbreak [28]. Should this information be shared, R&D
risks, time, and costs for the new indication would be significantly reduced. A relevant exam-
ple is the sleeping sickness drug candidate fexinidazole; all preclinical data were published
online [29], which prompted studies in another indication (leishmaniasis) by another group
[30]. Such unrestricted “reuse” of existing data is a core aspect of OS approaches and allows
the rapid building of new projects from existing ones by distinct teams of researchers.
OS ultimately fosters an R&D system that is less wasteful: in the event a project is halted, all
data (including negative findings) remain in the public domain, allowing similarly informed
decisions by other parties in the future. It is estimated that 85% of the US$200 billion/year
spent globally on health and medical research is “wasted,” primarily because information is
not shared (~50% of registered clinical trials are never published in full, and ~50% of those
published are not sufficiently complete for others to interpret, use, or replicate the research
correctly), meaning that new studies cannot take advantage of previous research [31,32] and
patients are exposed to undue risk [33].
The approval process for a drug originating from an OS process will require that drug to
have an “applicant” who bears responsibility for the process in the same way as any other
drug approval. While this lacks an OS precedent to our knowledge, existing PPPs or non-
profit groups could in theory shoulder this burden should a sufficiently attractive therapeutic
candidate emerge, as has been the case for rectal artesunate [34]. The manufacture and dis-
tribution becomes an issue of market dynamics centered within the generics industry, fa-
cilitated by a derivative of the Creative Commons Attribution License (CC-BY), suitably
adapted to pharmaceutical products, which would allow data to be shared, adapted, and used
(including for the purpose of making a profit, if such a route can be found) on the sole condi-
tion that the creator is appropriately credited [35]. Openness permits reuse and is a barrier
to exclusivity.
If a promising drug candidate addressing a major public health burden is generated
through this process, it would be expected that significant public and philanthropic funds
would be available for further development. Such is already the case in the field of poverty-
related infectious diseases and neglected tropical diseases, in which there is a traditional type
of what is often termed “market failure,” and other financing mechanisms, such as crowdfund-
ing [36] and prizes [37], are being piloted. There are recent precedents of drugs being taken
through such stages with government or philanthropic money and in the absence of patent
protection [38], as well as an increasing number of major new funding mechanisms designed
to assist with such efforts [39]. We see OS as a key means to achieve the aims of the London
Declaration [40] and OS projects as good candidates for support from the proposed Pooled
Fund [41]. Several innovative financing mechanisms have been created for global health [42],
and these could possibly be leveraged to support global health R&D.
Yet the potential is broader. The enormous toll on our society from cancer led former
United States Vice President Biden to urge researchers to “break down silos and bring all the
cancer fighters together—to work together, share information, and end cancer as we know it”
as part of the Cancer Moonshot initiative [43]. There are persistent calls for new approaches to
the development of antibacterials to counteract the looming threat of antimicrobial resistance
(AMR) [44]. Given the magnitude of the problem of dementia, it is conceivable that govern-
ments of countries in which the population is shifting progressively towards old-age citizens
would be willing to invest in the development of affordable treatments (in ways that the private
sector cannot) [45], rather than being overwhelmed by the eventual costs of patient care (US
$226 billion in 2015 for dementia in the US alone) [46]. Consortia and funds are being estab-
lished to tackle these threats without correspondingly new approaches in how the underlying
research is being conducted. We see OS as providing that genuinely new approach.
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A competing model
Drug development following a traditional secretive model but funded by governments has
been attempted. OS drug development (funded from whatever source) has not. Given society’s
continued unmet medical needs and the scientific, efficiency, and ethical imperatives that exist
to change the way in which we encourage medical innovation, there is a strong need to try
alternative systems. We have the technologies to allow massive data sharing and crowdsourc-
ing of research in real time. Furthermore, the borderless nature of OS work makes an R&D
program amenable to a wide range of different funders working cooperatively, safe in the
knowledge that the funding is not supporting any unnecessary duplication of effort.
One can envisage an organizational structure for OS pharma involving (1) an overarching
organization that manages the legal and regulatory aspects of running projects, (2) projects
themselves that are funded (by those stakeholders with the relevant resources) to achieve specific
milestones, and (3) a collaboration between a funded scientific core and the wider scientific com-
munity that is able to respond to project needs by virtue of the openness of the process. Tradi-
tional funding from public or philanthropic sources could (1) leverage other investments from
the private sector for specific project hurdles, and (2) stimulate significant in-kind contributions
from individuals or organizations interested in the solution of a problem or demonstration of
expertise. Communities of experts tend to coalesce around an OS project [47], lending it a signif-
icant research momentum that makes it competitive with more traditional closed approaches.
In November 2015, the United Nations Secretary General established a High-Level Panel to
find solutions to promote innovation and access to medicines, vaccines, and diagnostics to
ensure the health and well-being of all, realizing that the current commercially driven system
based on intellectual property rights fails to do so [48]. The report recommended that “the world
must take bold new approaches to both health technology innovation and ensuring access so
that all people can benefit from the medical advances that have dramatically improved the lives
of millions around the world in the last century.” If current calls for radical new approaches to
solving major problems in public health are serious, then solutions that seem risky precisely
because they subvert our traditional approaches should be embraced. OS pharma has that poten-
tial and should be trialed robustly as an alternative, competing model and one that brings genu-
inely fresh and powerful new methods to bear on our most serious public health challenges.
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